
A Possible Indicator of Responsiveness to Atezolizumab and Bevacizumab in Patients with Advanced HCC is a Plasma Growth Hormone
Plasma growth hormone is a potential indicator of response to atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma, according to a recent study that…